xxii
LABORATORY PRODUCTS
Most Common Cancer in UK Men has Chance for Earlier Detection
As consciousness of prostate cancer was heightened throughout March, during the annual Prostate Cancer Awareness Month, Roche in the UK launched its enhanced portfolio of tumour markers for the early detection of prostate cancer, giving health professionals across the UK access to simple and effective tools to help in the detection of prostate cancer, and for monitoring response to treatment.
The prostate cancer test from Roche, available for use by healthcare professionals, consists of two sensitive and specific assays for Prostate Specific Antigen (PSA) – the Elecsys® Elecsys®
Total PSA assay and the Free PSA assay. PSA measurement is currently considered to be the best method for identifying
risk of localised prostate cancer. This marker may lead to the detection of cancer at an early stage, before symptoms develop, when the cancer could be cured or treatment could extend life.
PSA is a substance produced by the prostate that helps in the mobility of sperm. A rise in PSA levels above the ‘normal’ range (PSA levels increase with age) may indicate infection, enlargement (benign prostatic hyperplasia), or cancer of the prostate. PSA measurement should be used in conjunction with DRE (Digital Rectal Examination), using age specific reference ranges. The additional measurement of percentage Free PSA helps to further differentiate between cancerous and non-cancerous conditions when total PSA is in the range of 4 to 10ng/mL and DRE is negative2. PSA measurements and DRE help to identify patients that may require further investigation. Used in combination, the Roche Elecys prostate-specific markers can give a valuable indication of the possible presence of prostate cancer in the early stages of the disease or when symptoms are not apparent.
Ian Parfrement, Director, Hospital In vitro Diagnostics at Roche, said “Although there is currently no population screening for prostate cancer, there is considerable demand for the PSA test amongst men worried about the disease and therefore this is a good opportunity to raise awareness of these enhanced markers.’
LAB PRODUCTS Circle no. 543
Affordable, Expandable Multicolour Flow Cytometry System
Building upon its powerful BD™ LSR cell analyser platform, BD Biosciences launched a new off-the- shelf BD LSRFortessa™ System, which uses up to four lasers - blue, red, violet and UV - that enable the detection of up to 18 colours simultaneously.
This new system occupies a 30’’x 36’’ benchtop footprint, allowing researchers to maximise utilisation of their lab space, without sacrificing system power. The system includes a number of innovative technologies, including novel collection optics that reduce excitation losses and improve light collection efficiency. The result is optical efficiency that delivers maximal sensitivity and resolution for multicolour applications.
“Our quest is to enhance cellular analysis by making multicolour flow cytometry analysis more powerful and accessible to life science researchers,” said James Glasscock, President, Cell Analysis, BD Biosciences. “This new BD LSRFortessa System is a perfect example of how we are offering researchers powerful, flexible, high-performance tools that will meet their needs today and tomorrow.”
As researchers’ needs grow, the new BD LSRFortessa System may be upgraded with additional or new lasers through the special order program to meet their precise assay requirements. This system is complemented by the special order BD LSRFortessa Cell Analyser, which was launched in June 2009. The special order BD LSRFortessa is customer configurable with up to five lasers, as well as a choice of more than 11 wavelengths, 30 positional choices for detectors, and multiple power options to meet researchers’ exact specifications.
The BD LSRFortessa System is the newest addition to the line of BD™ LSR cell analysers - the preferred tool of life science researchers worldwide working in core, academic, pharmaceutical and biotechnology laboratories.
Circle no. 544 LAB PRODUCTS Circle no. 545
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196 |
Page 197 |
Page 198 |
Page 199 |
Page 200 |
Page 201 |
Page 202 |
Page 203 |
Page 204 |
Page 205 |
Page 206 |
Page 207 |
Page 208 |
Page 209 |
Page 210 |
Page 211 |
Page 212 |
Page 213 |
Page 214 |
Page 215 |
Page 216 |
Page 217 |
Page 218 |
Page 219 |
Page 220
